Genmab A/S (GMAB)
51.37
-0.37
(-0.72%)
USD |
NASDAQ |
Nov 13, 16:00
52.12
+0.74
(+1.45%)
After-Hours: 06:26
Genmab Net Income (Quarterly) : 341.65M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 341.65M |
| June 30, 2026 | 302.57M |
| March 31, 2026 | 53.20M |
| December 31, 2025 | 30.98M |
| September 30, 2025 | 399.18M |
| June 30, 2025 | 340.52M |
| March 31, 2025 | 195.13M |
| December 31, 2024 | 549.88M |
| September 30, 2024 | 186.41M |
| June 30, 2024 | 203.20M |
| March 31, 2024 | 192.88M |
| December 31, 2023 | 92.29M |
| September 30, 2023 | 307.12M |
| June 30, 2023 | 195.03M |
| March 31, 2023 | 30.27M |
| December 31, 2022 | 80.03M |
| September 30, 2022 | 349.41M |
| June 30, 2022 | 270.52M |
| March 31, 2022 | 70.11M |
| December 31, 2021 | 110.04M |
| September 30, 2021 | 141.07M |
| June 30, 2021 | 49.61M |
| March 31, 2021 | 177.50M |
| December 31, 2020 | 93.06M |
| September 30, 2020 | 83.21M |
| Date | Value |
|---|---|
| June 30, 2020 | 498.80M |
| March 31, 2020 | 39.66M |
| December 31, 2019 | 218.11M |
| September 30, 2019 | 80.01M |
| June 30, 2019 | 12.77M |
| March 31, 2019 | 10.99M |
| December 31, 2018 | 127.51M |
| September 30, 2018 | 27.95M |
| June 30, 2018 | 41.65M |
| March 31, 2018 | 32.77M |
| December 31, 2017 | 124.31M |
| September 30, 2017 | -0.8972M |
| June 30, 2017 | 45.50M |
| March 31, 2017 | 2.308M |
| December 31, 2016 | 121.89M |
| September 30, 2016 | 28.34M |
| June 30, 2016 | 25.53M |
| March 31, 2016 | -1.703M |
| December 31, 2015 | 57.14M |
| September 30, 2015 | 20.89M |
| June 30, 2015 | 2.444M |
| March 31, 2015 | 32.79M |
| December 31, 2014 | 11.59M |
| September 30, 2014 | 28.43M |
| June 30, 2014 | -4.805M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 4.207B |
| Incyte Corp. | -784.80M |
| Ascendis Pharma A/S | 85.11M |
| Zealand Pharma A/S | -8.311M |
| Bavarian Nordic A/S | 68.79M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.186B |
| Total Expenses (Quarterly) | 844.13M |
| EPS Diluted (Quarterly) | 0.5475 |
| Enterprise Value | 34.93B |
| Gross Profit Margin (Quarterly) | 90.31% |
| Profit Margin (Quarterly) | 28.81% |
| Earnings Yield | 2.27% |
| Operating Earnings Yield | 4.01% |
| Normalized Earnings Yield | 2.835 |